Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Corneal densitometry for monitoring amiodarone therapy

Poster Details

First Author: M.Alnawaiseh GERMANY

Co Author(s):    L. Zumhagen   N. Eter                 

Abstract Details

Purpose:

To evaluate the effect of AK on the corneal backscattered light using the Pentacam densitometry module and to explore the correlation of cumulative dose and duration of treatment with plasma concentrations of amiodarone and with corneal densitometry.

Setting:

University Eye Hospital Muenster, Germany

Methods:

In this study 66 patients receiving amiodarone therapy were examined using the Oculus Pentacam�Â�®. Densitometry data were extracted, analyzed and compared with densitometry values of 66 healthy controls. Duration of treatment, cumulative dose, Orlando-stage (slit lamp biomicroscopy), serum concentration of amiodarone and N-desethylamiodarone were also determined and the correlation to different densitometry data was evaluated.

Results:

The total corneal light backscatter at total corneal thickness and at total diameter was significantly higher in the amiodarone-group compared with the control group (p < 0.001). Dividing the corneal surface into different layers at total thickness, the differences were significant in all layers (p < 0.001). The serum concentrations of the metabolite N-desethylamiodarone correlates with different densitometry values, especially in the 0-2 mm annulus in the anterior layer (r= 0.419;p= 0.001) and the cumulative dose and duration of treatment correlate significantly with the densitometry values in the 0-2 mm annulus at total thickness (p= 0.014 and p= 0.022 consecutively).

Conclusions:

Corneal micro-deposits involve not only the epithelium. The serum level of the active metabolite N-desethylamiodarone correlates with the extent of the keratopathy in the anterior layer, whereas chronic changes in the stoma correlate with the cumulative dose and duration of treatment.

Financial Disclosure:

NONE

Back to Poster listing